(Total Views: 233)
Posted On: 03/15/2019 10:54:38 PM
Post# of 154678
From that article.
We will have revenue in 2020,” he said.
Cytodyn has received offers from commercialization companies “with significant upfront and milestone payments for our products,” Pourhassan said. In addition, “a large biologics manufacturing” company has agreed to make half a billion dollars worth of Cytodyn’s product with no payment due until the end of 2020.
He believes the company needs $30 million more to finish its application and get Cytodyn to the point of achieving revenue. If it inks a licensing deal with an upfront payment, it won’t need to do another stock offering, Pourhassan said.
“With our product, we have shown in 670 patients we had zero serious adverse events. I don’t think any HIV drug out there has zero.”
We will have revenue in 2020,” he said.
Cytodyn has received offers from commercialization companies “with significant upfront and milestone payments for our products,” Pourhassan said. In addition, “a large biologics manufacturing” company has agreed to make half a billion dollars worth of Cytodyn’s product with no payment due until the end of 2020.
He believes the company needs $30 million more to finish its application and get Cytodyn to the point of achieving revenue. If it inks a licensing deal with an upfront payment, it won’t need to do another stock offering, Pourhassan said.
“With our product, we have shown in 670 patients we had zero serious adverse events. I don’t think any HIV drug out there has zero.”
(0)
(0)
